[HTML][HTML] The global landscape of EBV-associated tumors
C Shannon-Lowe, A Rickinson - Frontiers in oncology, 2019 - frontiersin.org
Epstein-Barr virus (EBV), a gamma-1 herpesvirus, is carried as a life-long asymptomatic
infection by the great majority of individuals in all human populations. Yet this seemingly …
infection by the great majority of individuals in all human populations. Yet this seemingly …
[HTML][HTML] Epstein Barr virus: development of vaccines and immune cell therapy for EBV-associated diseases
X Cui, CM Snapper - Frontiers in Immunology, 2021 - frontiersin.org
Epstein-Barr virus (EBV) is the first human tumor virus discovered and is strongly implicated
in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated …
in the etiology of multiple lymphoid and epithelial cancers. Each year EBV associated …
Immune cells and immunotherapy for cardiac injury and repair
Cardiac injury remains a major cause of morbidity and mortality worldwide. Despite
significant advances, a full understanding of why the heart fails to fully recover function after …
significant advances, a full understanding of why the heart fails to fully recover function after …
Epstein–Barr virus: more than 50 years old and still providing surprises
It is more than 50 years since the Epstein–Barr virus (EBV), the first human tumour virus, was
discovered. EBV has subsequently been found to be associated with a diverse range of …
discovered. EBV has subsequently been found to be associated with a diverse range of …
[HTML][HTML] Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
S Prockop, E Doubrovina, S Suser… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND Adoptive transfer of donor-derived EBV-specific cytotoxic T-lymphocytes
(EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation of …
(EBV-CTLs) can eradicate EBV-associated lymphomas (EBV-PTLD) after transplantation of …
EBV persistence—introducing the virus
DA Thorley-Lawson - Epstein Barr Virus Volume 1: One Herpes Virus …, 2015 - Springer
Persistent infection by EBV is explained by the germinal center model (GCM) which provides
a satisfying and currently the only explanation for EBVs disparate biology. Since the GCM …
a satisfying and currently the only explanation for EBVs disparate biology. Since the GCM …
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
SA Rosenberg, NP Restifo, JC Yang… - Nature Reviews …, 2008 - nature.com
Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged
as the most effective treatment for patients with metastatic melanoma and can mediate …
as the most effective treatment for patients with metastatic melanoma and can mediate …
Epstein–Barr virus: 40 years on
LS Young, AB Rickinson - Nature Reviews Cancer, 2004 - nature.com
Epstein–Barr virus (EBV) was discovered 40 years ago from examining electron
micrographs of cells cultured from Burkitt's lymphoma, a childhood tumour that is common in …
micrographs of cells cultured from Burkitt's lymphoma, a childhood tumour that is common in …
Population dynamics of immune responses to persistent viruses
MA Nowak, CRM Bangham - Science, 1996 - science.org
Mathematical models, which are based on a firm understanding of biological interactions,
can provide nonintuitive insights into the dynamics of host responses to infectious agents …
can provide nonintuitive insights into the dynamics of host responses to infectious agents …
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
T-cell immunotherapy that takes advantage of Epstein-Barr virus (EBV)–stimulated immunity
has the potential to fill an important niche in targeted therapy for EBV-related cancers. To …
has the potential to fill an important niche in targeted therapy for EBV-related cancers. To …